摘要
肝纤维化由多种慢性肝损伤发展而来,晚期可进展为肝硬化甚至肝细胞癌。活化的肝星状细胞(HSC)所产生的大量细胞外基质累积及各种促纤维化因子是肝纤维化进展的关键。微RNA(miRNA)作为一种非编码小RNA,可通过与特定的靶信使RNA结合,在转录后水平影响下游各种信号通路及蛋白的表达,并调控HSC的状态及其他肝纤维化过程。肝纤维化时,miRNA表达失调,肝脏及循环中的差异性表达miRNA及其相关成分可能成为诊断肝纤维化的潜在分子标志物及治疗靶点。
Hepatic fibrosis,developed from a variety of chronic liver injuries,can progress to cirrhosis or even hepatocellular carcinoma at the late stage.The accumulation of extracellular matrix and various pro-fibrosis factors produced by activated hepatic stellate cell(HSC)are the keys to the progression of liver fibrosis.MicroRNA(miRNA),a kind of small non-coding RNA,can affect the expression of downstream signaling pathways and proteins at the post-transcriptional level and regulate the condition of HSC and fibrogenesis through combining with specific target messenger RNA.Due to the dysregulation of miRNA during hepatic fibrosis,the variance of the expression of miRNA and its related components in the liver and the circulation could be the potential diagnostic molecular markers and therapeutic targets of hepatic fibrosis.
作者
李燚
陈睿
蒙增萍
申涌
陈瑜
刘咏梅
LI Yi;CHEN Rui;MENG Zengping;SHEN Yong;CHEN Yu;LIU Yongmei(School of Clinical Laboratory,Guizhou Medical University,Guiyang 550025,China;Department of Acupuncture and Massage,the Affiliated Hospital of Guizhou Medical University,Guiyang 550004,China;Center for Clinical Laboratories,the Affiliated Hospital of Guizhou Medical University,Guiyang 550004,China)
出处
《医学综述》
CAS
2021年第21期4177-4182,共6页
Medical Recapitulate
基金
国家自然科学基金(81960118)
贵州省科技计划项目(黔科合基础〔2020〕1Y300)。
关键词
肝纤维化
肝星状细胞
微RNA
分子标志物
治疗靶点
Hepatic fibrosis
Hepatic stellate cell
MicroRNA
Molecular marker
Therapeutic target
